应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02186 绿叶制药
休市中 04-19 16:08:35
2.610
-0.010
-0.38%
最高
2.630
最低
2.550
成交量
1,675万
今开
2.600
昨收
2.620
日振幅
3.05%
总市值
98.18亿
流通市值
98.18亿
总股本
37.62亿
成交额
4,339万
换手率
0.45%
流通股本
37.62亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
绿叶制药04月19日获主力加仓46万元 环比增加666.67%
自选股智能写手 · 04-19 16:15
绿叶制药04月19日获主力加仓46万元 环比增加666.67%
绿叶制药04月18日主力资金流入6万元 连续3日加仓
自选股智能写手 · 04-18 16:15
绿叶制药04月18日主力资金流入6万元 连续3日加仓
吉林敖东去年炒股亏7658万,拟再拿不超过10亿元加仓
成都商报红星新闻 · 04-17
吉林敖东去年炒股亏7658万,拟再拿不超过10亿元加仓
南向资金4月12日净卖出绿叶制药49.30万股 连续3日减持
自选股智能写手 · 04-15
南向资金4月12日净卖出绿叶制药49.30万股 连续3日减持
【券商聚焦】天风证券维持绿叶制药(02186)“买入”评级 指核心业务主要品种市场空间大
金吾财讯 · 04-10
【券商聚焦】天风证券维持绿叶制药(02186)“买入”评级 指核心业务主要品种市场空间大
绿叶制药04月08日遭主力抛售228万元 环比增加484.62%
自选股智能写手 · 04-08
绿叶制药04月08日遭主力抛售228万元 环比增加484.62%
绿叶制药盘中异动 早盘急速拉升5.13%
自选股智能写手 · 04-02
绿叶制药盘中异动 早盘急速拉升5.13%
华安证券:维持绿叶制药(02186)“买入”评级 2023年销售收入快速增长
智通财经网 · 04-01
华安证券:维持绿叶制药(02186)“买入”评级 2023年销售收入快速增长
绿叶制药(02186)产品销售稳健增长,创新项目出海可期
招商证券 · 03-29
绿叶制药(02186)产品销售稳健增长,创新项目出海可期
港股异动 | 绿叶制药(02186)午后跌近5% 全年纯利同比下跌11.9% 肿瘤产品销售收入下滑8%
智通财经 · 03-28
港股异动 | 绿叶制药(02186)午后跌近5% 全年纯利同比下跌11.9% 肿瘤产品销售收入下滑8%
绿叶制药发布2023年度业绩 股东应占溢利5.33亿元同比减少11.94%
新浪港股 · 03-28
绿叶制药发布2023年度业绩 股东应占溢利5.33亿元同比减少11.94%
“第二曲线”增长开启?一家老牌药企的转型与上岸
格隆汇 · 03-28
“第二曲线”增长开启?一家老牌药企的转型与上岸
《公司业绩》绿叶制药(02186.HK)全年纯利5.33亿元人民币跌11.9% 不派息
阿斯达克财经 · 03-28
《公司业绩》绿叶制药(02186.HK)全年纯利5.33亿元人民币跌11.9% 不派息
绿叶制药(02186)发布2023年度业绩 股东应占溢利5.33亿元 同比减少11.94%
智通财经网 · 03-28
绿叶制药(02186)发布2023年度业绩 股东应占溢利5.33亿元 同比减少11.94%
绿叶制药发布2023年全年业绩
美通社 · 03-27
绿叶制药发布2023年全年业绩
绿叶制药:血脂康胶囊使用的红曲原料和小林制药没有任何关联
澎湃新闻 · 03-27
绿叶制药:血脂康胶囊使用的红曲原料和小林制药没有任何关联
绿叶制药03月21日主力资金流出45万元 连续3日减仓
自选股智能写手 · 03-21
绿叶制药03月21日主力资金流出45万元 连续3日减仓
绿叶制药03月20日遭主力抛售50万元 环比增加400.00%
自选股智能写手 · 03-20
绿叶制药03月20日遭主力抛售50万元 环比增加400.00%
绿叶制药2023年度业绩及派息审议 3月27日董事会关键决策
和讯网 · 03-14
绿叶制药2023年度业绩及派息审议 3月27日董事会关键决策
绿叶制药(02186.HK)3月27日举行董事会会议批准年度业绩
金融界 · 03-14
绿叶制药(02186.HK)3月27日举行董事会会议批准年度业绩
加载更多
公司概况
公司名称:
绿叶制药
所属市场:
SEHK
上市日期:
--
主营业务:
绿叶制药集团有限公司是一家主要从事开发、生产、推广及销售药品的投资控股公司。公司及其子公司通过四大分部运营:肿瘤药物分部、心血管系统药物分部、消化与代谢药物分部和其他分部。该公司的主要产品包括用于癌症的化学治疗的备紫杉醇类制剂,用于实体肿瘤的放射治疗的注射用化合物,用于治疗高脂血症治疗的中药,用于治疗二型糖尿病的阿卡波糖胶囊,用于治疗老年痴呆症的卡巴拉汀透皮贴片等。产品以力扑素,希美纳,血脂康,麦通纳,贝希等品牌销售。该公司通过其子公司还从事提供合约研究及程序开发业务。该公司主要在中国内地运营业务。
发行价格:
--
{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"绿叶制药","latestPrice":2.61,"timestamp":1713514115031,"preClose":2.62,"halted":0,"volume":16753000,"delay":0,"floatShares":3761670643,"shares":3761670643,"eps":0.15426762,"marketStatus":"休市中","marketStatusCode":7,"change":-0.01,"latestTime":"04-19 16:08:35","open":2.6,"high":2.63,"low":2.55,"amount":43388110,"amplitude":0.030534,"askPrice":2.61,"askSize":191500,"bidPrice":2.59,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":0.1542676301041585,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"adjPreClose":2.62,"dividendRate":0.024461,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":2.311073436751681,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186","defaultTab":"news","newsList":[{"id":"2428687570","title":"绿叶制药04月19日获主力加仓46万元 环比增加666.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428687570","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428687570?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:15","pubTimestamp":1713514552,"startTime":"0","endTime":"0","summary":"04月19日, 绿叶制药股价跌0.38%,报收2.61元,成交金额4338万元,换手率0.45%,振幅3.05%,量比2.30。绿叶制药今日主力资金净流入46万元,连续4日净流入,上一交易日主力净流入6万元,今日环比增加666.67%。近一年数据显示,该股主力连续4日净流入后,次日上涨概率为33.33%,平均涨幅为1.32%。该股近5个交易日下跌4.74%,主力资金累计净流入167万元;近20日主力资金累计净流出428万元,其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191616188794af6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191616188794af6e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428909559","title":"绿叶制药04月18日主力资金流入6万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428909559","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428909559?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:15","pubTimestamp":1713428124,"startTime":"0","endTime":"0","summary":"04月18日, 绿叶制药股价跌0.76%,报收2.62元,成交金额2614万元,换手率0.27%,振幅3.41%,量比1.62。绿叶制药今日主力资金净流入6万元,连续3日净流入,上一交易日主力净流入134万元,今日环比减少95.52%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为52.63%,平均涨幅为1.17%。该股近5个交易日下跌7.42%,主力资金累计净流出145万元;近20日主力资金累计净流出484万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181615378b34bc39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181615378b34bc39&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428945033","title":"吉林敖东去年炒股亏7658万,拟再拿不超过10亿元加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428945033","media":"成都商报红星新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428945033?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:06","pubTimestamp":1713344811,"startTime":"0","endTime":"0","summary":"红星资本局4月17日消息,吉林敖东(000623.SH)昨日晚间公告,拟使用不超过10亿元的闲置自有资金进行证券投资。吉林敖东称,投资目的为进一步加强对公司及控股子公司持有的证券资产及闲置自有资金管理,提高公司资金使用效率,合理利用闲置自有资金,争取实现公司和股东收益最大化。2023年年报显示,吉林敖东在证券投资上的...","market":"us","thumbnail":"https://inews.gtimg.com/news_ls/Op7qliCy1_hyVJUvzSOufGcVMVGFBR8pef7PdZFLKMr-0AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/news_ls/Op7qliCy1_hyVJUvzSOufGcVMVGFBR8pef7PdZFLKMr-0AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240417A03A3Q00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240417A03A3Q00","is_publish_highlight":false,"gpt_icon":0},{"id":"2427094361","title":"南向资金4月12日净卖出绿叶制药49.30万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427094361","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427094361?lang=zh_cn&edition=full","pubTime":"2024-04-15 09:31","pubTimestamp":1713144675,"startTime":"0","endTime":"0","summary":"4月12日,南向资金减持绿叶制药49.30万股连续3日减持。截止当日收盘,港股通共持有绿叶制药148759.85万股,占流通股39.54%。港股通减持金额前五个股分别为腾讯控股、小鹏汽车-W、中国平安、汇丰控股、泡泡玛特。绿叶制药近5个交易日上涨2.24%,港股通累计减持550.10万股;近20个交易日下跌8.05%,港股通累计增持35.85万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404150946348b23b813&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404150946348b23b813&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426439802","title":"【券商聚焦】天风证券维持绿叶制药(02186)“买入”评级 指核心业务主要品种市场空间大","url":"https://stock-news.laohu8.com/highlight/detail?id=2426439802","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2426439802?lang=zh_cn&edition=full","pubTime":"2024-04-10 14:37","pubTimestamp":1712731036,"startTime":"0","endTime":"0","summary":"金吾财讯 | 天风证券发研报指,绿叶制药 公布2023年业绩:2023年整体营业收入61.4亿元,同比增长2.7%,产品销售收入56.3亿元,同比增长11.2%,归母净利润5.33亿,同比减少11.9%。净利润下降主要或是由于授权收入占比降低导致的。该行提到,后续核心产品销售放量及在研管线进度均值得期待,合理估值空间弹性大。该行指,考虑到公司新产品优势突出,将有多款药物上市,核心业务主要品种市场空间大,看好公司发展。维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200915/YWJkMTExMDAwMDkzNTUyODE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/YWJkMTExMDAwMDkzNTUyODE=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934786","is_publish_highlight":false,"gpt_icon":0},{"id":"2425959085","title":"绿叶制药04月08日遭主力抛售228万元 环比增加484.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425959085","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425959085?lang=zh_cn&edition=full","pubTime":"2024-04-08 16:15","pubTimestamp":1712564144,"startTime":"0","endTime":"0","summary":"04月08日, 绿叶制药股价涨3.73%,报收2.78元,成交金额1134万元,换手率0.11%,振幅2.24%,量比0.43。绿叶制药今日主力资金净流出228万元,连续3日净流出,上一交易日主力净流出39万元,今日环比增加484.62%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为75.00%,平均跌幅为1.33%。该股近5个交易日下跌2.82%,主力资金累计净流出41万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入217万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040816160487539502&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040816160487539502&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424136082","title":"绿叶制药盘中异动 早盘急速拉升5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424136082","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424136082?lang=zh_cn&edition=full","pubTime":"2024-04-02 09:47","pubTimestamp":1712022449,"startTime":"0","endTime":"0","summary":"2024年04月02日早盘09时47分,绿叶制药股票出现异动,股价快速拉升5.13%。机构评级方面,在所有4家参与评级的机构中,50%的券商给予买入建议,50%的券商给予卖出建议,无券商给予持有建议。绿叶制药股票所在的药品行业中,整体涨幅为0.11%。消息层面,截至09时47分,《华安证券:维持绿叶制药“买入”评级 2023年销售收入快速增长》资讯为影响绿叶制药的重要信息。中枢神经系统治疗领域的收入16.95亿元,同比增加28.1%,海内外产品增长发力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040209473087e7d74e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040209473087e7d74e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424576379","title":"华安证券:维持绿叶制药(02186)“买入”评级 2023年销售收入快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2424576379","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2424576379?lang=zh_cn&edition=full","pubTime":"2024-04-01 15:34","pubTimestamp":1711956855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,华安证券发布研究报告称,维持绿叶制药“买入”评级,预计2024-26年营业收入分别为68.11/83.95/99.25亿元,归母净利润为7.75/12.4/15.98亿元。2023年研发费用总额为5.87亿元,绝对值同比减少2.70亿元。三大领域收入悉数双位数增速,产品销售加速恢复报告期内,集团在肿瘤、心血管、中枢神经三大领域产品销售悉数获得双位数增长。肿瘤治疗领域的收入达21.22亿元,同比减少8.0%,其中除去授权合作收入外,产品纯销收入为19.20亿元,同比增加26.3%,增速恢复明显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096949.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423514109","title":"绿叶制药(02186)产品销售稳健增长,创新项目出海可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2423514109","media":"招商证券","top":-1,"share":"https://www.laohu8.com/m/news/2423514109?lang=zh_cn&edition=full","pubTime":"2024-03-29 09:20","pubTimestamp":1711675228,"startTime":"0","endTime":"0","summary":"产品销售稳健增长,销售费用支出逐步控制。在负债端,绿叶制药2023年流动负债81.4亿元,2022年同期94.9亿元,绝对额降低13.5亿元。公司2023年资产负债率46.9%,与2022年同期相比下降7.6个百分点,财务结构不断优化。多个创新产品获批上市,帕利哌酮晶体注射液出海可期。这意味着LY03010在其NDA审核过程中的专利挑战获得成功,后续有望成功出海,成为绿叶制药中长期的重要增长点。绿叶制药创新产品逐步兑现,资产负债结构改善,出海亦有看点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403291010378b7010e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403291010378b7010e8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422135119","title":"港股异动 | 绿叶制药(02186)午后跌近5% 全年纯利同比下跌11.9% 肿瘤产品销售收入下滑8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422135119","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422135119?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:37","pubTimestamp":1711607848,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,绿叶制药午后跌近5%,截至发稿,跌4.58%,报2.71港元,成交额2829.58万港元。公告称,于报告期内,集团肿瘤产品的销售收入减少至21.22亿元,同比减少约1.84亿元或8.0%;心血管系统产品销售收入增加至16.87亿元,同比增加约1.52亿元或9.9%;消化与代谢产品的销售收入减少至4.5亿元,同比减少约1.82亿元或28.8%;中枢神经系统产品的收入增加至16.95亿元,同比增加约3.72亿元或28.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094542.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422074977","title":"绿叶制药发布2023年度业绩 股东应占溢利5.33亿元同比减少11.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422074977","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2422074977?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:02","pubTimestamp":1711587751,"startTime":"0","endTime":"0","summary":"绿叶制药(02186)发布截至2023年12月31日止年度业绩,该集团期内取得收入61.43亿元(人民币,下同),同比增加2.7%;股东应占溢利5.33亿元,同比减少11.94%;每股基本盈利14.29分。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapvtry5797325.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapvtry5797325.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422974459","title":"“第二曲线”增长开启?一家老牌药企的转型与上岸","url":"https://stock-news.laohu8.com/highlight/detail?id=2422974459","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2422974459?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:21","pubTimestamp":1711585302,"startTime":"0","endTime":"0","summary":"3月27日晚间,绿叶制药(2186.HK)交出2023年的成绩单:集团实现营收61.4亿元,同比增长2.7%;税前利润7亿元,同比增长4.5%。","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/118.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/118.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/712975","is_publish_highlight":false,"gpt_icon":0},{"id":"2422352941","title":"《公司业绩》绿叶制药(02186.HK)全年纯利5.33亿元人民币跌11.9% 不派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2422352941","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422352941?lang=zh_cn&edition=full","pubTime":"2024-03-28 01:42","pubTimestamp":1711561320,"startTime":"0","endTime":"0","summary":"绿叶制药(02186.HK) 公布截至去年12月底止全年业绩,营业额61.43亿元人民币(下同),按年升2.7%。纯利5.33亿元,按年跌11.9%;每股盈利14.29分。不派息。(sw/t)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-27 16:25。)过往派息公布日期派息事项派息内容2023/08/29中期业绩无派息2023/03/29末期业绩无派息 2022/12/02特别报告优先发售:保证配额每6,638股股份的完整倍数可认购1股山东博安生物技术股份有限公司预留股份2022/08/29中期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200629165900329_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200629165900329_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337944/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422291090","title":"绿叶制药(02186)发布2023年度业绩 股东应占溢利5.33亿元 同比减少11.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422291090","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422291090?lang=zh_cn&edition=full","pubTime":"2024-03-28 00:16","pubTimestamp":1711556198,"startTime":"0","endTime":"0","summary":"绿叶制药(02186)发布截至2023年12月31日止年度业绩,该集团期内取得收入...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240328/20240328002113_76311.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240328/20240328002113_76311.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094204.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422914162","title":"绿叶制药发布2023年全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2422914162","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422914162?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:10","pubTimestamp":1711552200,"startTime":"0","endTime":"0","summary":"产品销售稳健增长,财务结构显著优化 上海2024年3月27日 /美通社/ -- 3月27日,绿叶制药集团发布2023年全年业绩及截至目前的业务进展。2023年新增3款新药获批,进一步强化集团在该领域竞争优势。该产品在国内持续高速增长,并在2023年国家医保药品目录中维持原医保支付标准成功续约。展望未来,开启新一轮高速增长 值此2024年集团成立30周年之际,集团多年布局的第一批创新品种密集落地,迎来丰收。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4372535_ZH72535_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422354779","title":"绿叶制药:血脂康胶囊使用的红曲原料和小林制药没有任何关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2422354779","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422354779?lang=zh_cn&edition=full","pubTime":"2024-03-27 13:52","pubTimestamp":1711518721,"startTime":"0","endTime":"0","summary":"近期,日本知名药企小林制药召回含有红曲成分保健品的事件受到关注。其中,“红曲”成分的安全性也备受关注。绿叶制药(2186.HK)的降血脂产品血脂康就是以红曲为原料制成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403273025960857.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403273025960857.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421067430","title":"绿叶制药03月21日主力资金流出45万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2421067430","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421067430?lang=zh_cn&edition=full","pubTime":"2024-03-21 16:15","pubTimestamp":1711008959,"startTime":"0","endTime":"0","summary":"03月21日, 绿叶制药股价涨1.68%,报收3.03元,成交金额2137万元,换手率0.19%,振幅2.35%,量比0.92。绿叶制药今日主力资金净流出45万元,连续3日净流出,上一交易日主力净流出50万元,今日环比减少10.00%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为75.00%,平均跌幅为0.84%。该股近5个交易日下跌0.65%,主力资金累计净流入393万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入435万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032116162887a0f264&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032116162887a0f264&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420794600","title":"绿叶制药03月20日遭主力抛售50万元 环比增加400.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420794600","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420794600?lang=zh_cn&edition=full","pubTime":"2024-03-20 16:16","pubTimestamp":1710922584,"startTime":"0","endTime":"0","summary":"03月20日, 绿叶制药股价涨1.71%,报收2.98元,成交金额1058万元,换手率0.10%,振幅2.73%,量比0.46。绿叶制药今日主力资金净流出50万元,上一交易日主力净流出10万元,今日环比增加400.00%。该股近5个交易日下跌0.99%,主力资金累计净流入731万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入329万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320161717879c29cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320161717879c29cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419601284","title":"绿叶制药2023年度业绩及派息审议 3月27日董事会关键决策","url":"https://stock-news.laohu8.com/highlight/detail?id=2419601284","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2419601284?lang=zh_cn&edition=full","pubTime":"2024-03-14 21:05","pubTimestamp":1710421534,"startTime":"0","endTime":"0","summary":"绿叶制药将于3月27日召开董事会会议审议年度业绩及派息事宜绿叶制药(02186.HK)近日宣布,将于2024年3月27日(星期三)举行董事会会议。会议将主要审议公司及其附属公司截至2023年12月31日的年度业绩。此外,董事会还将考虑是否派发末期股息。会议的召开意味着绿叶制药即将公布2023年度的财务状况。对于二级市场投资者而言,这将是关注公司业务发展及盈利能力的重要时刻。投资者需密切关注会议结果,以便了解公司业绩及未来派息计划。这将对绿叶制药的股票价格产生影响,进而影响投资者的投资决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403142125428781e4b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403142125428781e4b0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419670877","title":"绿叶制药(02186.HK)3月27日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2419670877","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419670877?lang=zh_cn&edition=full","pubTime":"2024-03-14 19:44","pubTimestamp":1710416678,"startTime":"0","endTime":"0","summary":"格隆汇3月14日丨 绿叶制药 (02186.HK)宣布,公司将于2024年3月27日(星期三)举行董事会会议,藉以(其中包括)批准公司及其附属公司截至2023年12月31日止的年度业绩及其发布,并考虑派发末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031419503187818bfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031419503187818bfc&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.0474},{"period":"1month","weight":-0.1242},{"period":"3month","weight":-0.1608},{"period":"6month","weight":-0.2346},{"period":"1year","weight":-0.3325},{"period":"ytd","weight":-0.3003}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"绿叶制药集团有限公司是一家主要从事开发、生产、推广及销售药品的投资控股公司。公司及其子公司通过四大分部运营:肿瘤药物分部、心血管系统药物分部、消化与代谢药物分部和其他分部。该公司的主要产品包括用于癌症的化学治疗的备紫杉醇类制剂,用于实体肿瘤的放射治疗的注射用化合物,用于治疗高脂血症治疗的中药,用于治疗二型糖尿病的阿卡波糖胶囊,用于治疗老年痴呆症的卡巴拉汀透皮贴片等。产品以力扑素,希美纳,血脂康,麦通纳,贝希等品牌销售。该公司通过其子公司还从事提供合约研究及程序开发业务。该公司主要在中国内地运营业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.026366},{"month":2,"riseRate":0.3,"avgChangeRate":0.013725},{"month":3,"riseRate":0.4,"avgChangeRate":-0.015714},{"month":4,"riseRate":0.4,"avgChangeRate":-0.009951},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034404},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.004427},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.004018},{"month":8,"riseRate":0.1,"avgChangeRate":-0.046856},{"month":9,"riseRate":0.6,"avgChangeRate":0.05059},{"month":10,"riseRate":0.6,"avgChangeRate":0.01699},{"month":11,"riseRate":0.6,"avgChangeRate":0.04117},{"month":12,"riseRate":0.4,"avgChangeRate":0.009706}],"exchange":"SEHK","name":"绿叶制药","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿叶制药,02186,绿叶制药股票,绿叶制药股票老虎,绿叶制药股票老虎国际,绿叶制药行情,绿叶制药股票行情,绿叶制药股价,绿叶制药股市,绿叶制药股票价格,绿叶制药股票交易,绿叶制药股票购买,绿叶制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}